A chronic strain of the cystic fibrosis pathogen Pandoraea pulmonicola expresses a heterogenous hypo-acylated lipid A.
Cystic Fibrosis
Lipid A
Lipopolysaccharide
MALDI-TOF Mass spectrometry
Pandoraea
Structural characterization
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
31
07
2020
accepted:
07
10
2020
revised:
16
09
2020
pubmed:
14
10
2020
medline:
4
3
2022
entrez:
13
10
2020
Statut:
ppublish
Résumé
Pandoraea sp. is an emerging Gram-negative pathogen in cystic fibrosis causing severe and persistent inflammation and damage of the lungs. The molecular mechanisms underlying the high pathogenicity of Pandoraea species are still largely unknown. As Gram-negatives, Pandoraea sp. express lipopolysaccharides (LPS) whose recognition by the host immune system triggers an inflammatory response aimed at the bacterial eradication from the infected tissues. The degree of the inflammatory response strongly relies on the fine structure of the LPS and, in particular, of its glycolipid moiety, i.e. the lipid A. Here we report the structure of the lipid A isolated from the LPS of a chronic strain of P. pulmonicola (RL 8228), one of the most virulent identified so far among the Pandoraea species. Our data demonstrated that the examined chronic strain produces a smooth-type LPS with a complex mixture of hypoacylated lipid A species displaying, among other uncommon characteristics, the 2-hydroxylation of some of the acyl chains and the substitution by an additional glucosamine on one or both the phosphate groups.
Identifiants
pubmed: 33048281
doi: 10.1007/s10719-020-09954-8
pii: 10.1007/s10719-020-09954-8
pmc: PMC8052242
doi:
Substances chimiques
Lipid A
0
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-144Références
Infect Immun. 2004 May;72(5):2837-42
pubmed: 15102794
Eur J Biochem. 1976 May 1;64(2):423-8
pubmed: 1278168
Am J Respir Crit Care Med. 2017 Dec 15;196(12):P23-P24
pubmed: 29243949
J Antimicrob Chemother. 2017 Nov 1;72(11):3035-3042
pubmed: 28961916
Mol Microbiol. 2003 May;48(3):725-36
pubmed: 12694617
Chemistry. 2017 Mar 13;23(15):3637-3647
pubmed: 28004420
J Lipid Res. 2002 Dec;43(12):2188-95
pubmed: 12454282
J Med Microbiol. 2011 Mar;60(Pt 3):289-299
pubmed: 21127160
Infect Immun. 2004 Sep;72(9):5340-8
pubmed: 15322031
Antimicrob Agents Chemother. 2006 Apr;50(4):1330-5
pubmed: 16569848
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
J Microbiol Methods. 2016 Jan;120:68-71
pubmed: 26656001
Paediatr Respir Rev. 2014 Jun;15 Suppl 1:13-5
pubmed: 24832700
Chemistry. 2015 Jan 7;21(2):500-19
pubmed: 25353096
J Med Microbiol. 2008 Jan;57(Pt 1):15-20
pubmed: 18065662
Chembiochem. 2019 Jan 18;20(2):230-236
pubmed: 30179300
Mar Drugs. 2018 Apr 11;16(4):
pubmed: 29641496
Chembiochem. 2013 Jun 17;14(9):1105-15
pubmed: 23733445
J Transl Med. 2017 Apr 27;15(1):84
pubmed: 28449677
J Bacteriol. 2008 Jun;190(12):4281-90
pubmed: 18424515
J Cyst Fibros. 2004 Dec;3(4):223-31
pubmed: 15698939
Mol Microbiol. 2012 Sep;85(5):962-74
pubmed: 22742453
Methods Enzymol. 2010;480:89-115
pubmed: 20816206
New Microbes New Infect. 2013 Nov;1(2):27-9
pubmed: 25356323
Glycobiology. 2016 Sep;26(9):907-910
pubmed: 27654115
J Biol Chem. 2015 Aug 28;290(35):21305-19
pubmed: 26160169
Mol Immunol. 2015 Feb;63(2):166-75
pubmed: 24856407
J Biochem Biophys Methods. 1993 Feb;26(1):81-6
pubmed: 8387076
FEMS Microbiol Rev. 2016 Jul;40(4):480-93
pubmed: 27075488